20567-67-3

Usage

Uses

Used in Pharmaceutical Research:
6-METHYL-3,4-DIHYDRO-2H-PYRIDO[3,2-B][1,4]OXAZINE is used as a research compound for the development of potential drug candidates due to its unique chemical structure and biological properties.
Used in Antitumor Applications:
In the pharmaceutical industry, 6-METHYL-3,4-DIHYDRO-2H-PYRIDO[3,2-B][1,4]OXAZINE is used as an antitumor agent, exhibiting pharmacological activities that make it a subject of interest for the development of cancer treatments.
Used in Antimalarial Applications:
6-METHYL-3,4-DIHYDRO-2H-PYRIDO[3,2-B][1,4]OXAZINE is also used as an antimalarial agent, showing potential in the development of treatments for malaria, a disease caused by Plasmodium parasites.

InChI:InChI=1S/C8H10N2O/c1-6-2-3-7-8(10-6)9-4-5-11-7/h2-3H,4-5H2,1H3,(H,9,10)

Upstream product

• 20348-10-1 6-methyl-2H-pyrido[3,2-b]-1,4-oxazin-3(4h)-one 
• 15128-90-2 6-methyl-2-nitropyridin-3-ol 
• 20348-16-7 2-amino-3-hydroxy-6-methylpyridine 

Downstream Products

• 381226-84-2 2,3-dihydro-6-methyl-4H-pyrido[3,2-b]-1,4-oxazine-4-carboxylic acid, 1,1-dimethylethyl ester 
• 855313-34-7 6-[2-(3-methyl-4-nitro-phenoxy)-ethyl]-2,3-dihydro-pyrido[3,2-b][1,4]oxazine-4-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Non-peptidic αvβ3 antagonists containing indol-1-yl propionic acids

We describe the synthesis and structure/activity relationship of RGD mimetics that are potent inhibitors of the integrin αvβ 3. Indol-1-yl propionic acids containing a variety of basic moieties at the 5-position, as well as substitutions alpha and beta to the carboxy terminus were synthesized and evaluated. Novel compounds with improved potency have been identified.

Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives

The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.

Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives

The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.

Substituted indoles and their use as integrin antagonists

The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.

Cycloalkyl alkanoic acids as integrin receptor antagonists

The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αVβ3 and/or αVβ5 integrin.